Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Amicable Agreement”

This article was originally published in The Gray Sheet

Executive Summary

Regardless of any positives or negatives associated with the protracted CEO transition at Boston Scientific, one primary driver for the arrangement appears to be an agreement hashed out between the company and Johnson & Johnson allowing Mahoney to make the move in the near term without flouting non-compete requirements for former J&J executives.
Advertisement

Related Content

Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War
Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War

Topics

Advertisement
UsernamePublicRestriction

Register

MT030532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel